[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-small-cell-lung-cancer-nsclc-stage-iv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-small-cell-lung-cancer-nsclc-stage-iv":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100658185","an-exploratory-clinical-study-of-bempemab-combined-with-anlotinib-as-first-line-treatment-for-elderly-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-100658185",false,"NCT07849712","An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer","Bemo-sufail Monoclonal Antibody Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer: An Exploratory Clinical Study","BEACON-OLD","Inclusion Criteria:Voluntary signed written Informed Consent Form (ICF). Age $\\\\ge 75$ years, male or female. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. Expected survival time $\\\\ge 3$ months. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC). Unresectable locally advanced (Stage IIIB\u002FIIIC) or metastatic (Stage IV) NSCLC that cannot receive radical concurrent\u002Fsequential chemoradiotherapy (according to the AJCC\u002FUICC 8th TNM staging). No EGFR sensitive mutations or ALK gene translocations. (Non-squamous NSCLC patients must provide prior tissue test reports; squamous NSCLC patients with unknown status do not require testing and are regarded as negative). Intolerant to or refusing chemotherapy\u002Fradiotherapy. At least one measurable target lesion per RECIST v1.1 that can be accurately measured repeatedly. Brain metastases are permitted. Adequate organ function (without blood components or growth factors within 7 days prior to treatment):Hematology: Absolute Neutrophil Count (ANC) $\\\\ge 1.5 \\\\times 10\\^9\u002F\\\\text{L}$; Platelets $\\\\ge 100 \\\\times 10\\^9\u002F\\\\text{L}$; Hemoglobin $\\\\ge 90\\\\text{ g\u002FL}$. Renal: Calculated Creatinine Clearance (CrCl) $\\\\ge 50\\\\text{ mL\u002Fmin}$ (Cockcroft-Gault formula); Urine protein $\\\\le 1+$ or 24-hour urine protein $\\\u003C 1.0\\\\text{ g}$. Hepatic: Total Bilirubin (TBil) $\\\\le 1.5 \\\\times \\\\text{ULN}$; AST and ALT $\\\\le 2.5 \\\\times \\\\text{ULN}$ ($\\\\le 5 \\\\times \\\\text{ULN}$ for patients with liver metastases); Serum Albumin $\\\\ge 28\\\\text{ g\u002FL}$. Coagulation: International Normalized Ratio (INR) and Activated Partial Thromboplastin Time (APTT) $\\\\le 1.5 \\\\times \\\\text{ULN}$. Cardiac: Left Ventricular Ejection Fraction (LVEF) $\\\\ge 50\\\\%$. Exclusion Criteria:Histopathological components of small cell lung cancer. Known driver gene-positive NSCLC eligible for standard targeted therapy. Active autoimmune disease requiring systemic treatment within the past 2 years. History of immunodeficiency; positive HIV antibody test; ongoing long-term systemic corticosteroids or immunosuppressive agents. Active tuberculosis or active syphilis infection. History of allogeneic organ or stem cell transplantation. History or current presence of non-infectious pneumonitis\u002Finterstitial lung disease requiring systemic glucocorticoids. Severe infection within 4 weeks prior to first dose; active infection requiring systemic anti-infective therapy within 2 weeks prior to first dose. Presence of brainstem, meningeal, or spinal cord metastases or compression. History of myocarditis, cardiomyopathy, or malignant arrhythmia; unstable angina, myocardial infarction, congestive heart failure, or vascular disease requiring hospitalization within 12 months prior to first dose. History of esophageal\u002Fgastric varices, severe ulcer, unhealed wound, gastrointestinal perforation\u002Ffistula\u002Fobstruction, or acute GI bleeding within 6 months prior to first dose. Arterial thromboembolism, Grade $\\\\ge 3$ venous thromboembolism, TIA, CVA, hypertensive crisis, or uncontrolled hypertension ($\\\\text{SBP} \\\\ge 160\\\\text{ mmHg}$ or $\\\\text{DBP} \\\\ge 100\\\\text{ mmHg}$) within 6 months prior to first dose. Severe bleeding tendency or coagulation disorder; clinically significant hemoptysis within 1 month prior to first dose.","ALL","75 Days",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","This exploratory clinical study evaluates the efficacy and safety of combining benmelstobart (a PD-L1 inhibitor) with anlotinib (a multi-target anti-angiogenic TKI) as a first-line, chemotherapy-free treatment for elderly patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).",[27,28,29],"Non-small Cell Lung Cancer (NSCLC) Stage IV","Locally Advanced Non-Small Cell Lung Cancer","Metastatic Non-small Cell Lung Cancer",[31,32,33,34,35],"Non-Small Cell Lung Cancer","Advanced Non-Small Cell Lung Cancer","PD-L1 Inhibitor","Anti-Angiogenesis","Benmelstobart","NOT_YET_RECRUITING","2026-09-26",{"date":39,"type":40},"2026-09-30","ACTUAL",{"date":42,"type":21},"2026-10-01",{"date":44,"type":21},"2028-12-31",{"name":46,"class":47},"Zhejiang Cancer Hospital","OTHER","Non-small Cell Lung Cancer (NSCLC), Stage IV"]